Q（Question）

When a physician or pharmacist requests information on off-label use of one's own product, is it permissible to provide the information on the spot, assuming the representative is prepared to give an appropriate answer to the specific request?

A（MHLW answer）

Providing information on the spot when a physician or pharmacist requests information on off-label use of one's own product is not prohibited. However, the handling of off-label use information must comply with Part 4-3 of the Guidelines, including limiting the recipients of the information to the requesting party.

So what (meaning): On-the-spot provision of off-label information is not prohibited; however, the Part 4-3 conditions — especially limiting recipients to the requesting individual — must be met even in real-time interactions.

So why (rationale): The format of providing information immediately in person is not itself a basis for prohibition; the substantive conditions of the Guidelines apply regardless of timing.

Commentary — background, application, practical notes

Part 4-3 of the Guidelines sets conditions for the provision of off-label use information — including that it be provided in response to a request and that recipients be limited to the requester — but places no restriction on the timing or location of provision. Q11 confirms this point, making explicit that providing information on the spot when a physician or pharmacist asks for off-label information during a visit is not prohibited for reasons of form alone.

A typical scenario is a physician asking during a meeting with an MR 'is there any safety data for using this drug off-label for [condition]?' The prerequisite is that the representative is prepared to give an appropriate response at that moment — relevant literature, IF entries, or internally reviewed response materials. If that preparation is not in place, 'I will get back to you on that' is the appropriate response.

A common practical error is blanket self-restraint based on the belief that providing off-label information on the spot is categorically prohibited. Q11 was issued specifically to correct this, but at the same time, the condition to 'limit recipients to the requesting party' must be strictly observed even in real-time settings. If off-label information is conveyed to other physicians, MRs, or company staff present in the room, this may violate the recipient-limitation condition, and the circumstances of the meeting environment must therefore be considered.